Cargando…

Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis

PURPOSE: Compare treatment switching rates and costs among biologic-naive psoriasis patients initiating apremilast or biologics. METHODS: This retrospective claims analysis used IBM MarketScan Commercial and Medicare Supplemental databases to identify patients who initiated apremilast or a biologic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaplan, David L, Ung, Brian L, Pelletier, Corey, Udeze, Chuka, Khilfeh, Ibrahim, Tian, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373411/ https://www.ncbi.nlm.nih.gov/pubmed/32765022 http://dx.doi.org/10.2147/CEOR.S251775

Ejemplares similares

Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
por: Wu, Jashin J., et al.
Publicado: (2020)

Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis
por: Gao, Jia C, et al.
Publicado: (2022)

Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database
por: Husni, M Elaine, et al.
Publicado: (2022)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective
por: Zargaran, Marzieh, et al.
Publicado: (2021)

Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis
por: Tanaka, Masayuki, et al.
Publicado: (2021)

Pediatric psoriasis treated with apremilast
por: Smith, Rebecca L.
Publicado: (2016)

Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience
por: De, Abhishek, et al.
Publicado: (2020)

Characterizing Outcomes and Unmet Needs Among Patients in the United States with Mild-to-Moderate Plaque Psoriasis Using Prescription Topicals
por: Gupta, Shaloo, et al.
Publicado: (2021)

Erythrodermic Psoriasis Treated with Apremilast
por: Arcilla, John, et al.
Publicado: (2016)

Treatment of erythrodermic psoriasis with apremilast
por: Gioe, Olivia A., et al.
Publicado: (2021)

Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic
por: De, Abhishek, et al.
Publicado: (2019)

Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis
por: Sun, Helen Y., et al.
Publicado: (2021)

Apremilast or Methotrexate: The Arrows in the Quiver for Psoriasis
por: Panda, Gautam, et al.
Publicado: (2023)

A Comparative Study of the Efficacy of Methotrexate versus Methotrexate with Apremilast in Moderate to Severe Chronic Plaque Psoriasis
por: Srivastava, Divyanshu, et al.
Publicado: (2023)

Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
por: Gottlieb, Alice B., et al.
Publicado: (2021)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Recurrence of Melanoma after Starting Apremilast for Psoriasis
por: Salopek, Thomas G.
Publicado: (2017)

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
por: Reich, K., et al.
Publicado: (2018)

The cost of biologics for psoriasis is increasing
por: Cheng, Judy, et al.
Publicado: (2014)

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2020)

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer, Stephan, et al.
Publicado: (2015)

Recurrent generalized pustular psoriasis possibly triggered by apremilast
por: Wang, Wen-Ming, et al.
Publicado: (2020)

A case of erythrodermic psoriasis successfully treated with apremilast
por: Megna, Matteo, et al.
Publicado: (2021)

The Cost Effectiveness of Biologic Therapy for the Treatment of Chronic Plaque Psoriasis in Real Practice Settings in Italy
por: Spandonaro, Federico, et al.
Publicado: (2014)

Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2015)

Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
por: Sfikakis, Petros P., et al.
Publicado: (2023)

Mycobacterium kansasii infection in a psoriasis patient treated with adalimumab and switch to apremilast: First report and literature review
por: Brunasso, Alexandra Maria Giovanna, et al.
Publicado: (2021)

Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort
por: BETTUZZI, Thomas, et al.
Publicado: (2022)

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
por: Nash, Peter, et al.
Publicado: (2018)

Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece [Corrigendum]
Publicado: (2015)

Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study
por: Giofrè, Claudia, et al.
Publicado: (2023)

Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
por: Afra, T. P., et al.
Publicado: (2019)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
por: Verbenko, Dmitry A., et al.
Publicado: (2020)

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan, Murlidhar, et al.
Publicado: (2021)

Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients
por: Cohen-Sors, Raphaella, et al.
Publicado: (2021)

Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO
por: Reich, Kristian, et al.
Publicado: (2021)

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
por: Ruggiero, Angelo, et al.
Publicado: (2023)

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
por: Palfreeman, Andrew C, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qv9u2ngosrhcguqu764kajbg9o